EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

8-K - Neos Therapeutics, Inc. (0001467652) (Filer)

425 - Neos Therapeutics, Inc. (0001467652) (Subject)

S-8 POS - Neos Therapeutics, Inc. (0001467652) (Filer)

S-8 POS - Neos Therapeutics, Inc. (0001467652) (Filer)

S-8 POS - Neos Therapeutics, Inc. (0001467652) (Filer)

S-8 POS - Neos Therapeutics, Inc. (0001467652) (Filer)

– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 12, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system

– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 10, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system

PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2020. “Despite the unique challenges of 2020, Hercules was able to reach several new financial and operating milestones,” stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. “Notably, we closed over $1.0 billion in new debt and equity commitments

– Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that the companies’ respective special meetings of stockholders related to the proposed merger between Aytu and Neos have been set f

DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available for on-demand viewing on the Investor Relations page of the company’s website at http://investors.neostx.com/ beginning Monday, January 11, 2021 at 6:00 a.m. ET. A replay of the webcast will be available on Neos’ website for 30 days. About Neos Therapeutics

Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022  Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class prescription therapeutics and consumer health productsCompanies to host joint conference call today at 8:30 am ET ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company foc

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-12) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 10/13/2023. Application Category: NDA, Application Number: 205489, Application Classification: Labeling

Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-7) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 06/25/2021. Application Category: NDA, Application Number: 205489, Application Classification: Labeling